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Background: Primary liver cancer (PLC) is a common cancer worldwide, especially in developing countries. Several
previous studies using different datasets have summarized PLC incidence rates and trends in different populations.
However, with changes in exposure to risk factors and the implementation of preventive measures, the
epidemiology of PLC worldwide may have changed.
Methods: We extended the analyses using the latest data from Cancer Incidence in Five Continents over the
35-year period 1973–2007 from 24 populations in Americas, Asia, Europe and Oceania using Joinpoint regression
analysis. We examined age-standardized rates (ASRs) of PLC by histologic subtypes for both males and females in
24 populations during the period 2003–2007.
Results: We found that during the period 2003–2007, the highest ASRs for PLC were observed in some Asian
populations, ranging from 19.0 to 26.7 per 100,000 in males and 4.8 to 8.7 per 100,000 in females. The international
trends between 1973 and 2007 showed that ASRs for PLC were declining in several Asian populations. In contrast,
ASRs for PLC were increasing in some European, American and Oceanian populations.
Conclusions: Although the reasons were not fully clear for these trends, public health measures in Asian
populations and HCV transmission in European, American and Oceanian populations were likely to have
contributed to these patterns. Meanwhile, other possible risk factors such as the consumption of alcohol, obesity,
and nonalcoholic fatty liver disease should also be concerned for the burden of PLC.
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It was estimated that for the year 2012, primary liver
cancer (PLC) incidence rates ranked fifth in men and
ninth in women worldwide [1]. The number of incident
cases of PLC was estimated to be 782,000 per year,
including 554,000 in men and 228,000 in women [1].
PLC mortality rates ranked the second in both sexes in
the world [1]. Five-year relative survival rate for USA
tends to be 16.6% based on data from the Surveillance,
Epidemiology, and End Results (SEER) (2004–2010)
Program of the US National Cancer Institute [2]. In
China, the age-standardized 5-year relative survival rate
for liver cancer was 10.1% [3]. PLC is the major type of
liver cancer, which is composed of several histologic* Correspondence: daiminlyon@gmail.com
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unless otherwise stated.subtypes, including hepatocellular carcinoma (HCC),
cholangiocarcinoma (CC), and combined hepatocellular
carcinoma and cholangiocarcinoma (cHCC-CC) [4].
Most of the PLC cases (85%) are diagnosed in develop-
ing countries. The highest incidence rates have been
reported in the regions of Southeast Asia and sub-
Saharan Africa [5]. In these high-incidence populations,
except for Japan, chronic infection with hepatitis B virus
(HBV) and aflatoxin exposure were recognized as major
risk factors for PLC. In low-incidence populations, how-
ever, PLC was mainly associated to the chronic hepatitis
C virus (HCV) infection. It was estimated that most
HCC cases (approximately 80%) were associated with
HBV and/or HCV infections [6]. Moreover, some recent
studies indicated that alcohol-related liver diseases,
smoking, immigration, and obesity were also possible
risk factors linking to PLC [7-9].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sets had reported the international trends in PLC
incidence rates, one of which [12] reported the global
PLC incidence rates and trends for 1993–2002 (10-year
period). However, with changes in exposure to risk
factors and the implementation of protective measures,
the epidemiology of PLC worldwide may have changed.
To give a longer-term and more recent comprehensive
picture on the current status of PLC worldwide, we
extended the analyses for the 35-year period from 1973
to 2007 from 24 populations in Americas, Asia, Europe
and Oceania. This data may provide more useful evi-
dence for evaluating the effect of previous measures of
PLC prevention and control, and may facilitate the
development of future measures.
Methods
Incidence data
To examine the changing trends in the incidence of PLC
over time, age-standardized (by Segi’s world standard
population [13]) incidence rates (ASRs) by sex were
obtained from Volumes 4–10 of Cancer Incidence in
Five Continents (CI5) from the website of the Inter-
national Agency for Research on Cancer (IARC) [14-20]
in which all data is publicly available. Volumes 4–10 of
CI5 generally provided data by 5-year periods: 1973–
1977, 1978–1982, 1983–1987, 1988–1992, 1993–1997,
1998–2002 and 2003–2007. Incidence data from 2003 to
2007 by histologic subtypes (HCC, CC, other & unspeci-
fied carcinoma) were collected from 24 populations in
four continents from Vol. 10 of CI5. Classification of
PLC from Vols. 4, 5–8 and 9–10 of CI5 was coded ac-
cording to the International Classification of Diseases
(ICD) 8th (155), 9th (155) and 10th (C22) revisions,
respectively.
Populations were chosen for inclusion in our study on
the basis of the following criteria: (1) incidence for time
periods at least as far back as 1983–1987; (2) an absence
of changes in population coverage or of warnings
regarding data quality reported in CI5 Vols. 4–10; and
(3) a sufficiently large number of registered cases in CI5
Vol. 10 to enable analyses of recent rates by histologic
subtypes (trends by histologic subtypes were not included
in our study). Only one registry from each country was
selected; if more than one registry met the basic criteria,
the registry with the largest population was included
in the analysis (expect for China which included
Hong Kong and Shanghai). Twenty four populations
were selected: four from the Americas (Canada, British
Columbia [BC]; Colombia, Cali; USA, SEER: (9 registries:
California: San Francisco; Connecticut; Georgia: Atlanta;
Hawaii; Iowa; Michigan: Detroit; New Mexico; Utah;
Washington: Seattle) Black/White), six from Asia (China,
Hong Kong; China, Shanghai; India, Mumbai; Israel: Jews;Japan, Osaka Prefecture; Singapore: Chinese), five from
Northern Europe (Denmark; Finland; Norway; Sweden;
UK, England, North Western Region [NWR]), three from
Western Europe (France, Bas-Rhin; Germany, Saarland;
Switzerland, Geneva), four from elsewhere in Europe
[21] (Southern and Central & Eastern Europe including
Italy, Varese Province; Poland, Cracow; Slovakia; Spain,
Navarra), and two from Oceania (Australia, New South
Wales [NSW]; New Zealand). No African populations
met all the inclusion criteria. However, four African
populations (Algeria, Setif Wilaya; Egypt, Gharbiah;
Uganda, Kyadondo; Zimbabwe, Harare: African) were
chosen to describe the PLC incidence rates in the last
time interval (2003–2007).
Incidence data for white and black populations in US
were not included in CI5 vol. four (1973–1977) and vol.
five (1978–1982), so we further referred to the US SEER
dataset [22]. The SEER program is a population-based
cancer registry system covering 18 registries and 28%
of the US population. Long-term data from 1973 to
2010 were available from nine registries that included
approximately 9.4% of the US population (based on
2010 census).
For New Zealand, we abstracted the data for 1983–1987
and 1988–2002 from CI5plus [23] which was part of CI5
databases and contained annual incidence data for a single
registry or a group of populations in one country. The
data for the last time period 2003–2007 were obtained
from CI5 vol. 10.Data analysis
Incidence trends in ASRs of PLC were analyzed using
Joinpoint regression (Joinpoint regression software, Version
3.5.3-May 2012, available through the Surveillance Research
Program of the US National Cancer Institute). The permu-
tation method was used for significance tests. Changes in
annual incidence rates from PLC were calculated as annual
percentage change (APC) in each segment. In the final
model, the Joinpoint analysis provided average annual
percentage change (AAPC). The significant test of APC
and AAPC to 0 was also conducted.
Age-standardized incidence rates of PLC by histologic
subtypes (HCC, CC and other & unspecified carcinoma)
and sex for selected populations during the period
2003–2007 were integrated and calculated. Secular trends
in ASRs were examined by registry and sex for every five-
year period during 1973–2007. PLC trends from New
Zealand were described during five-year periods from
1983–1987 to 2003–2007. Figures displaying the incidence
trends were prepared using a semi-log scale to facilitate
the comparison of temporal trends as well as magnitude.
These data were plotted at the midpoint of each five-year
interval.
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ASRs for PLC in 2003–2007 were highest in some pop-
ulations of Asia (China, Hong Kong; Japan; China,
Shanghai; Singapore: Chinese) and Africa (Egypt and
Zimbabwe), and much lower in most populations in
Europe, Americas and Oceania (Tables 1 and 2). In
Asian populations, ASRs for PLC were ranging from
19.0 to 26.7 per 100,000 in males and 4.8 to 8.7 per
100,000 in females, except for India and Israel (Jews)
(5.2 and 3.1 per 100,000 in males, 2.4 and 1.4 per
100,000 in females, respectively). In most populations
in Americas, Europe and Oceania, PLC incidence rates
varied between 2.2-7.8 per 100,000 for males and 1.0-3.7
per 100,000 for females except for France (13.6 per
100,000 for males and 2.5 per 100,000 for females),
Switzerland (13.1 per 100,000 for males and 3.0 per
100,000 for females), Italy (12.6 per 100,000 for males and
3.7 per 100,000 for females), and USA, Black population
(11.6 per 100,000 for males and 3.1 per 100,000 for
females).
Tables 1 and 2 also showed the results of Joinpoint
analysis for ASRs in males and females for all ages,
respectively. The secular trends in PLC incidence among
24 populations from 1973 to 2007 were presented in
Figure 1. The increasing trends for both males and
females in PLC incidence rates were seen in most of
the populations in Europe, Americas, and Oceania. UK,
England, France, Germany, Switzerland, Italy, Canada,
Colombia, USA: Black, USA: White, Australia, and New
Zealand (1982–2007) showed a significant increasing
trend across all the periods (Tables 1 and 2 and Figure 1).
In males, ASRs for PLC in Germany, USA, Black, and
USA, White increased significantly from the period
1982–1987 (Table 1 and Figure 1A). PLC incidence rates
in France, Canada and Australia significantly increased
from 1973–1977, leveled off in the 1990s (Table 1 and
Figure 1A). ASRs for PLC in Spain significantly increased
by 28.9% per year from 1973–1977, significantly decreased
by 1.8% per year from 1982–1987, whereas ASRs for PLC
in Finland, Norway, Sweden, Poland and Slovakia leveled
off in all the period (Table 1 and Figure 1A). In females,
the pattern of PLC incidence in each population seemed
to be similar except for Denmark, Poland and Spain
(Table 2 and Figure 1B). ASRs for PLC in Poland signifi-
cantly decreased by 3.1% per year from 1973–1977 to
2003–2007, whereas ASRs for PLC in Denmark and Spain
showed stable trends from 1973–1977 to 2003–2007.
However, in Asia, ASRs for PLC for both males and
females showed significant decreasing trends in two of
the six populations (China, Shanghai; Singapore: Chinese)
from 1973–1977 to 2003–2007 (Tables 1 and 2 and
Figure 1A and B). The stable trends among males and
females were seen in two of the six populations (China,
Hong Kong and Israel: Jews) from 1973–2007 to 2003–2007. ASRs for PLC in one of the six populations
(Japan) significantly increased by 23.0% in males and
23.5% in females from 1973–1977 and reached a plat-
eau in 1990s (Tables 1 and 2 and Figure 1A and B).
Whereas ASRs for PLC for females in India signifi-
cantly increased by 5.3% from 1973–1977 and leveled
off in 1980s (Table 2 and Figure 1B).
According to the ASRs of PLC by histologic subtypes
from 2003 to 2007, HCC was the leading histologic
subtype, followed by CC and other & unspecified carcin-
oma (Figure 2). The highest incidence rate of HCC was
observed in China, Hong Kong (8.5 per 100,000 in males
and 1.9 per 100,000 in females), and the lowest one was
shown in UK England (0.9 per 100,000 in males and 0.3
per 100,000 in females). The highest incidence of CC
was seen in France (2.0 per 100,000 in males and 0.7 per
100,000 in females), followed by other European coun-
tries including Spain (1.1 per 100,000 in males and 0.6
per 100,000 in females), Finland (1.0 per 100,000 in
males and 0.7 per 100,000 in females), and Italy (1.0 per
100,000 in males and 0.6 per 100,000 in females). China,
Hong Kong (0.9 per 100,000 in males and 0.7 per
100,000 in females) and Japan (0.9 per 100,000 in males
and 0.5 per 100,000 in females) had relatively higher
incidence of CC than other Asian countries.
Discussion
International trends in PLC incidence rates during the
period 1973–2007 showed that the PLC incidence rates
increased in most European, American and Oceanian
populations, although these age-standardized PLC inci-
dence rates in 2003–2007 were much lower than these in
Asia. Meanwhile, PLC incidence rates decreased in Asian
populations, although their age-standardized PLC inci-
dence rates in 2003–2007 were the highest in the world.
PLC is a common cancer, particularly in Asia countries
such as China, Japan and Singapore (Chinese). Among
these countries, PLC is closely associated with hepatitis
virus infection (HBV infection in China and Singapore,
HCV infection in Japan) and exposure to aflatoxin (in
China). In our study, the decreasing trends in China and
Singapore may be attributed to some public health mea-
sures [24-27]. HBV vaccination was incorporated into
the national childhood immunization program by China
and Singapore from the middle 1980s to the early 1990s.
The immunization coverage with three doses of HBV
vaccine was 70.7%-95.0% in 1999 [28,29]. Several studies
also reported the decreases in PLC incidence rates in
China, particularly in Shanghai and in younger age groups
[24,30]. Another study in Taiwan showed that the age-
and sex- adjusted rate ratios for individuals aged 5 to
29 years decreased by more than 80% for HCC incidence
from 1977–1980 to 2001–2004 [25]. In Singapore, Chia
et al. [26] suggested that a general declining trend in liver
Table 1 International variation in primary liver cancer incidence rates for males, from 1973–1977 to 2003-2007
Populations Period of registryestablished
Mean
of MV%1 1973-1977 2003-2007 Joinpoint analyses (1973-2007)
Cases Rate2 Cases Rate2 Trend 1 Period Trend 2 APC3 (%) Period APC3 (%) AAPC4 (%)
Northern Europe
Denmark 1953-1957 88.0 424 2.9 947 4.1 1975-2005 0.8# 0.8#
(1973-1976)
Finland 1959-1961 88.3 473 3.2 1,192 5.2 1975-2005 1.2 1.2
(1971-1976)
Norway 1959-1961 85.7 230 1.6 421 2.2 1975-2005 0.8 0.8
Sweden 1959-1961 95.7 1,162 3.4 1,465 3.4 1975-2005 -0.7 -0.7
(1971-1975)
UK, England, NWR 1973-1977 44.7 157 1.1 1,250 4.4 1975-1985 6.0# 1985-2005 3.9# 4.6#
Western Europe
France, Bas-Rhin 1975-1977 64.1 76 4.9 547 13.6 1975-1990 6.4# 1990-2005 0.5 3.4#
(1975-1977)
Germany, Saarland 1968-1972 64.5a 86 2.4 394 7.5 1975-1985 4.6 1985-2005 3.6# 3.9#
Switzerland, Geneva 1970-1972 70.3 100 9.7 214 13.1 1975-2005 0.9# 0.9#
Europe, Other
Italy, Varese Province 1976-1977 55.5 64 6.9 516 12.6 1975-2005 2.6# 2.6#
(1976-1977)
Poland, Cracow 1965-1966 42.3 89 5.9 103 4.8 1975-2005 -1.5 -1.5
(2003-2006)
Slovakia 1973-1977 55.1 183 3.1 1,052 6.4 1975-2005 2.6 2.6
Spain, Navarra 1973-1977 51.2 8 0.5 217 7.8 1975-1985 28.9# 1985-2005 -1.8# 7.5#
Americas
Canada, BC 1969-1972 56.5 142 2.0 201 5.2 1975-1995 3.7# 1995-2005 2.3 3.3#
Colombia, Cali 1967-1971 71.8 22 1.9 178 4.2 1975-2005 2.1# 2.1#
(1972-1976)
USA, SEER: Black 1973-1975 78.0b 154c 4.4 936 11.6 1975-1985 1.2 1985-2005 4.1# 3.1#
USA, SEER: White 1973-1975 74.7b 1,009c 2.1 4,443 5.9 1975-1985 1.4 1985-2005 4.6# 3.5#
Oceania
Australia, NSW 1973-1977 73.8 139 1.1 1,379 5.4 1975-1995 6.5# 1995-2005 4.4 5.8#











Table 1 International variation in primary liver cancer incidence rates for males, from 1973–1977 to 2003-2007 (Continued)
Asia
China, Hong Kong 1974-1977 46.8 2,515 34.4 6,503 26.7 1975-2005 -0.8 -0.8
(1974-1977)
China, Shanghai 1975 14.2 949 31.7 6,128 21.7 1975-2005 -1.4# -1.4#
(1975)
India, Mumbai 1964-1966 60.3 145 2.7 1,195 5.2 1975-2005 1.4 1.4
(1973-1975)
Israel: Jews 1960-1966 65.7 226 2.9 559 3.1 1975-2005 0.1 0.1
(1972-1976)
Japan, Osaka Prefecture 1966-1966 43.2 935 5.6 11,922 25.6 1975-1985 23.0# 1985-2005 -3.4 4.7#
Singapore: Chinese 1968-1972 32.3 843 32.2 1,451 19.0 1975-2005 -1.8# -1.8#
Africa
Algeria, Setif Wilaya 1986-1989 9.8 - - 48 1.9 - - - - -
Egypt, Gharbiah 2003-2007 24.7 - - 1,806 24.8 - - - - -
Uganda, Kyadondo 2003-2007 29.9 - - 177 11.4 - - - - -
Zimbabwe, Harare: African 2003-2006 12.1 - - 199 16.7 - - - - -
(2003-2006)
1Mean of MV% (Percentage of morphologically verified cases) was calculated from 1978 to 2007. 2Rate is age-standardized to the world population, per 100,000 person-years. 3APC, Annual Percent Change.4AAPC,
Average Annual Percent Change. #APC/AAPC is significantly different from 0 (two-side p<0.05).











Table 2 International variation in primary liver cancer incidence rates for females, from 1973–1977 to 2003-2007
Populations Period of registryestablished
Mean
of MV%1 1973-1977 2003-2007 Joinpoint analyses (1973-2007)
Cases Rate2 Cases Rate2 Trend 1 Period Trend 2 APC3 (%) Period APC3 (%) AAPC4 (%)
Northern Europe
Denmark 1953-1957 82.8 308 1.6 434 1.6 1975-2005 -0.4 -0.4
(1973-1976)
Finland 1959-1961 82.1 391 1.7 701 2.1 1975-2005 0.1 0.1
(1971-1976)
Norway 1959-1961 78.2 117 0.6 240 1.0 1975-2005 1.0 1.0
Sweden 1959-1961 94.3 754 1.8 859 1.7 1975-2005 -1.1 -1.1
(1971-1975)
UK, England, NWR 1973-1977 38.4 75 0.4 863 2.3 1975-2005 5.3# 5.3#
Western Europe
France, Bas-Rhin 1975-1977 56.4 18 0.7 133 2.5 1975-2005 3.9# 3.9#
(1975-1977)
Germany, Saarland 1968-1972 54.4a 77 1.5 207 2.9 1975-2005 2.0# 2.0#
Switzerland, Geneva 1970-1972 66.9 23 1.3 66 3.0 1975-2005 2.4# 2.4#
Europe, Other
Italy, Varese Province 1976-1977 48.9 37 2.7 224 3.7 1975-2005 1.0# 1.0#
(1976-1977)
Poland, Cracow 1965-1966 32.2 116 4.3 70 2.4 1975-2005 -3.1# -3.1#
(2003-2006)
Slovakia 1973-1977 52.2 190 2.6 619 2.4 1975-2005 0.6 0.6
Spain, Navarra 1973-1977 38.1 11 0.6 89 2.2 1975-2005 1.4 1.4
Americas
Canada, BC 1969-1972 52.6 87 1.1 97 1.7 1975-2005 1.2# 1.2#
Colombia, Cali 1967-1971 72.5 19 1.5 182 3.2 1975-1985 1.6 1985-2005 3.4# 2.8#
(1972-1976)
USA, SEER: Black 1973-1975 72.1b 68c 1.5 336 3.1 1975-1985 0.7 1985-2005 3.2# 2.4#
USA, SEER: White 1973-1975 71.0b 613c 1.0 1,762 1.9 1975-1985 0.7 1985-2005 3.0# 2.2#
Oceania
Australia, NSW 1973-1977 71.7 56 0.4 634 1.9 1975-1990 3.6 1990-2005 7.7# 5.6#











Table 2 International variation in primary liver cancer incidence rates for females, from 1973–1977 to 2003-2007 (Continued)
Asia
China, Hong Kong 1974-1977 44.0 741 8.9 2,001 6.9 1975-2005 -0.6 -0.6
(1974-1977)
China, Shanghai 1975 13.1 278 9.1 2,419 7.1 1975-1985 1.5 1985-2005 -2.2# -1.0#
(1975)
India, Mumbai 1964-1966 54.3 43 1.0 567 2.4 1975-1985 5.3# 1985-2005 0.4 2.0#
(1973-1975)
Israel: Jews 1960-1966 55.9 102 1.3 341 1.4 1975-2005 0.1 0.1
(1972-1976)
Japan, Osaka Prefecture 1966-1966 39.3 249 1.2 5,689 8.7 1975-1985 23.5# 1985-2005 -1.6 6.2#
Singapore: Chinese 1968-1972 30.1 231 7.1 471 4.8 1975-1985 -0.8 1985-2005 -1.9# -1.5#
Africa
Algeria, Setif Wilaya 1986-1989 92.5 - - 40 1.6 - - - - -
Egypt, Gharbiah 2003-2007 24.2 - - 433 6.2 - - - - -
Uganda, Kyadondo 2003-2007 29.0 - - 131 8.7 - - - - -
Zimbabwe, Harare: African 2003-2006 13.9 - - 101 13.9 - - - - -
(2003-2006)
1Mean of MV% (Percentage of morphologically verified cases) was calculated from 1978 to 2007. 2Rate is age-standardized to the world population, per 100,000 person-years. 3APC, Annual Percent Change.4AAPC,
Average Annual Percent Change. #APC/AAPC is significantly different from 0 (two-side p<0.05).











Figure 1 Trends in age-standardized primary liver cancer incidence rates by continent and area for the time period 1973–2007: A.
Males B. Females.
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Chinese. Although the measure had no an effect on
general population, we expect it will play an important
role in the reduction of PLC incidence rates in the
coming decades. Moreover, dietary aflatoxin exposure
declined in the high-incidence areas of PLC seemed to
have contributed to the decrease in PLC incidence in
China [31]. A study in Qidong, China [31], where afla-
toxin exposures were common, had reported that the
decreasing liver cancer incidence in population over
25 years could mainly be attributable to the reduction
of exposure to aflatoxin from 1980 to 2008.
In Japan, there were different trends between 1973–
1992 and 1988–2007. The increasing trends started in
1973–1977 and reached peak in 1988–1992. This was
thought to be in part due to the spread of HCV infec-
tion, which began in the 1920s and increase after World
War II with an explosion in parenteral amphetamine use
and paid blood donation [32,33]. Although APC did not
significantly decrease during 1988–2007, the decline in
PLC incidence had been continuously seen from 1988–
1992 in our analysis. Stiffening of legal penalties against
amphetamine use starting in 1954 and conversion from
paid to voluntary blood donation in late 1960s mighthave reduced HCV transmission [34]. After the discov-
ery of HCV RNA, HCV screening tests for first- and
second-generation HCV antibodies started in 1989 and
1992, respectively [35]. These tests were adopted by the
Red Cross Blood Center for screening blood, which fur-
ther decreased the risk of post-transfusion hepatitis. The
Japanese government has taken urgent comprehensive
countermeasures against hepatitis (HBV and HCV) and
HCC since 2002 [33]. Therefore, these measures would
provide a significant contribution to decrease the num-
ber of patients suffering from HCV-related liver diseases
including PLC.
In contrast, PLC was not a very common cancer in
European, American and Oceanian countries where there
were no epidemic regions of HBV infection. However, an
increasing trend of PLC incidence rates was seen in most
of these populations which were partly due to the wide-
spread HCV infection associated with drug use, exposure
to contaminated blood transfusion and/or needles used
for medical purposes [36]. The natural history of PLC
indicated that the time between exposure to HCV and
development of HCC is about 30 years [37]. HCV infec-
tions were found in 30-50% of HCC patients in the United
States and 44-66% of HCC patients in Italy [38]. Both of
Figure 2 Age-standardized primary liver cancer incidence rates by histologic subtypes for selected populations for the time period
2003–2007.
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their own continent. The different peak years of HCV
infection prevalence for each country were likely respon-
sible for the respective peaks in PLC incidence rates. The
increasing trends in PLC incidence rates in the United
States could be attributed to increased HCV exposures by
contact with contaminated blood and injection drug use
during the 1960s and 1970s [39]. In Italy, the upsurge of
liver cancer incidence after 1970s was in part attributable
to HCV infection caused by the re-use of disposable
syringes among intravenous drug users without proper
disinfection [40]. Meanwhile, in several studies conducted
in Western countries, 30 to 40% of patients with HCC did
not have chronic infection with HBV or HCV, suggesting
alternative causes [5]. Other factors including alcohol
[41,42], obesity [43,44], and non-alcoholic fatty liver dis-
ease (NAFLD) [5] might be contributed to the increasing
trend. In population-based cohort studies in the United
States and Scandinavia [44-46], HCC was 1.5 to 2.0 timesas likely to develop in obese persons as in those who were
not obese. NAFLD, which is present in up to 90% of all
obese persons and up to 70% of persons with type 2
diabetes, has been proposed as a possible risk factor for
HCC [47]. Although there were still some difficult
problems in the latency period from exposure to these
factors and PLC development, more emphasis should
be recommended to control these factors.
The advent of precise diagnostic tests may increase
recognition of the disease, which accounts for a rising
incidence, rather than a true increase in its occurrence
[48]. Ultrasonography, measurement of serum alpha-
fetoprotein, and computed tomography scanning have
been routinely used since the early 1980s, which should
lead to an increase in the number of hepatic biopsies
conducted. However, the percentage of histologically
confirmed PLC has not increased significantly during the
study period in these countries which had an increasing
trend in PLC incidence rates. In addition, females in
Zhang et al. BMC Cancer  (2015) 15:94 Page 10 of 11Poland (from 1973–1977 to 2003–2007) and males in
Spain (from 1982–1987 to 2003–2007) also exhibited a
decreasing trend of PLC incidence rates. The reasons for
this decreasing trend remain unclear.
This study has several strengths. The data were ab-
stracted from large, well-established registries throughout
the world. For the first time, data covering 35 years were
analyzed to describe the variation of international trends
in PLC incidence rates, which may stimulate further etio-
logic research. In addition, incidence rates for particular
histologic subtypes of PLC in different populations were
examined separately. One limitation of this study was that
trends by histologic subtypes were not examined. The
variation of ICD coding might influence the interpretation
of our results. In our study, ICD coding contained ICD-8
(Malignant neoplasm of liver and intrahepatic bile ducts,
specified as primary), ICD-9 (Malignant neoplasm of liver,
specified as primary) and ICD-10 (Malignant neoplasm of
liver and intrahepatic bile ducts, specified as primary). CC
was not included in ICD-9 (period from 1978–1982 to
1993–1997). Therefore, the changes in PLC rates mainly
reflect changes of HCC. Our study was also limited by the
lack of nationwide cancer registries in some countries,
thus registration data might not accurately reflect the true
patterns in the respective countries.Conclusions
Our analysis on CI5 data suggested that ASRs for PLC
were declining in several Asian countries where the
highest incidence rates were still seen between 1973 to
1977 and 2003 to 2007. On the contrary, ASRs for PLC
were increasing in some American, European and Oceanian
countries. HBV vaccination programs and screening tests
might play an important role in deceasing trends in Asia.
Although the reasons of the increasing trends in American,
European and Oceanian populations were not fully clear,
the variation was likely to be due to in part the increasing
prevalence of HCV infection. While a vaccine for HBV is
widely available in most developed and developing coun-
tries, there is currently no vaccine available for HCV.
Therefore, it is a critical for HCV infection prevention that
blood donations are screened, safe injection practices are
used at all times, and unnecessary injections are avoided.
Additionally, controlling other risk factors such as alcohol
consumption, obesity, and NAFLD may help to reduce
PLC incidence rates.
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